Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SANGUINE CORP. (SGNC) -- Ignore unavailable to you. Want to Upgrade?

To: Mike Ankley who wrote (3003)	7/11/1998 7:49:00 PM
From: chirodoc	Read Replies (2) \| Respond to of 5402

<<<<Heres 3 people from Price Waterhouse describing Biotech Valuations: .thanks--bookmarked it and will come back to it thanks curtis

To: Mike Ankley who wrote (3003)	7/11/1998 10:52:00 PM
From: Mr. Forthright	Read Replies (1) \| Respond to of 5402

Great research. A lot of it sounds familiar. Doesn't it? <<Yet it is still imperative that a value can be estimated within a reasonable range for practical purposes such as raising capital, negotiating strategic alliances and joint venture agreements, investment decisions, and licensing strategies. Investors need to benchmark the company against other companies, to evaluate whether the market's valuation for biotech companies are efficient or not.>> <<The development life cycle is very long, on average ranging anywhere from 16 to 20 years.>> <<For example, in the drug development and approval process, only one in five thousand compounds that enter preclinical testing make it to human testing, and then only one in five are approved. Of those products which are approved, few biotechnology products which reach the market generate sufficient return to cover their cost.>>

To: Mike Ankley who wrote (3003)	7/12/1998 3:06:00 AM
From: Mike Ankley	Read Replies (2) \| Respond to of 5402

Here's a couple links from the FDA site regarding the FDA's reinventing itself in order to speed up the approval process: fda.gov fda.gov One excerpt from the second link is as follows: Shortening Review Times for New Drugs and Devices 1) FDA now uses expert review panels to expedite the review of certain biotechnology products. (For example, a joint committee of FDA experts oversaw the licensing in record time of the drug interferon beta 1b to treat certain patients with multiple sclerosis.) 2) Under the Prescription Drug User Fee Act of 1992, drugs are now reviewed more quickly. This law authorizes FDA to charge user fees for drug applications, and to use these additional resources for the reviews of new drugs, vaccines, and biotechnology products. Already, review times for new chemical drugs have dropped from an average of 30 months in 1992 to 20 months in 1994.(1) By 1997, FDA will be getting these products to market in a year or less, as fast as or faster than anywhere else in the world, with no sacrifice in review quality. Cheers Mike